David O'Malley, MD, discusses the increased benefit of rucaparib maintenance in patients with ovarian cancer who express RAD51C/D mutations.
David O’Malley, MD, professor in the Department of Obstetrics and Gynecology at The Ohio State University College of Medicine, and director of the Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center—The James, discusses the increased benefit of rucaparib (Rubraca) maintenance in patients with ovarian cancer who express RAD51C/D mutations.
In the phase III ARIEL3 trial, investigators examined the clinical benefit of rucaparib maintenance treatment following disease progression in a subgroup of patients with ovarian cancer whose disease is associated with a mutation in a non-BRCA homologous recombination (HRR) gene, says O’Malley. Results showed that a subgroup of patients with a RAD51C/D mutation experienced a significantly longer progression-free survival (PFS) with rucaparib compared with those who received placebo.
Specifically, the PFS in patients with RAD51C/D mutations who received rucaparib was around 25 months compared with 5.5 months in patients who received placebo, according to O’Malley (P =.0184) The benefit of rucaparib maintenance is pronounced in all patients with a mutation in a non-BRCA HRR gene, but patients with RAD51C/D gene mutations appear to experience far greater benefit with PARP maintenance, concludes O’Malley.